Back

Short-term risk of haemorrhage during heparin bridging at initiation of vitamin K antagonist therapy in patients with non-valvular atrial fibrillation managed in ambulatory care

27 August 2016 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Antithrombotic therapy in atrial fibrillation 1 Atrial fibrillation (AF) ESC Premium Access ESC Congress 2016

About the speaker

Photo
Doctor Kim Bouillon

French National Agency for Medicines and Health Products Safety (ANSM), Saint Denis (France)

5 More presentations in this session

Presentation thumbnail
Atrial fibrillation in haemodialysis patients without a vitamin K antagonist: Insight from the RAKUEN study
Doctor W. Mitsuma (Niigata, JP)
Abstract Slides
Presentation thumbnail
Alcohol abuse is associated with increased risk of ischemic stroke in low risk patients with non-valvular atrial fibrillation.
Doctor F. Al-Khalili (Stockholm, SE)
Abstract Slides
Presentation thumbnail
Do baseline characteristics account for geographical variations in event rates in patients with newly diagnosed atrial fibrillation? The GARFIELD-AF registry
Professor K. Fox (Edinburgh, GB)
Abstract Slides
Presentation thumbnail
Death, stroke and major bleeding risk in patients older than 85 years with atrial fibrillation
Doctor Y. Arnson (Kfar Saba, IL)
Abstract Slides
Presentation thumbnail
Increased use of oral anticoagulants in patients with atrial fibrillation: Nationwide temporal trends in Denmark from 2005 to 2015
Mr K. Gadsboell (Hellerup, DK)
Abstract Slides

Access the full session

Session thumbnail
Antithrombotic therapy in atrial fibrillation 1

The Event

Event poster

ESC Congress 2016

27 August - 31 August 2016

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources